VENLO, THE NETHERLANDS and BRENTFORD, UK -- (MARKET WIRE) -- May 21, 2007 -- QIAGEN (Nasdaq: QGEN, Frankfurt, Prime Standard: QIA), the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics and Whatman (WHM.L), a global leader in separation and life science enabling technologies, today announced a non-exclusive distribution partnership that provides QIAGEN with the right to market and sell Whatman FTA® and FTA-based kits to all QIAGEN's target markets including life science research, molecular diagnostics and applied testing.
